Simon Van Wambeke

Medical Oncologist

[Daniel E Spratt @DrSpratticus]

1/n X-torial on our recent @NEJMEvidence paper out: https://t.co/t8byAg2lJn

Should all men w/ conventional imaging defined mHSPC receive doublet or triplet systemic therapy?

[MediMix @Medi_Mix]

🚨Highlights from #ESMO2024! Dr Tom Van den Mooter & Dr @StrijbosMichiel share key findings on Ra-223, enzalutamide, and new AR ligands in mCRPC.
Watch now! 👀https://t.co/upNJMtvfgF #MediMix #Oncology #GUCancer #ProstateCancer #CancerResearch #ClinicalTrials

[Tom Powles @tompowles1]

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer. Published in @nejm

https://t.co/qCZqTiaJpO

[Michiel Strijbos @StrijbosMichiel]

ARANOTE:

Giving ADT monotherapie to de novo high volume patients ....REALLY???
What ethics board approved that? After STAMPEDE and CHAARTED....

@OncoAlert

[Simon Van Wambeke @SimonWambeke]

@NEJM Same result as low doze olanzapine in unselected patients? https://t.co/C9FKn5UpcL

[Charles Jiang MD, MPH @CharlesJiangMD]

Important #alliance trial! oxybutinin 5mg bid provided strong benefits in reducing hot flashes for prostate cancer patients on ADT+/-abi. No safety concern.

[Piet Ost @piet_ost]

Immensely grateful for having received the #ESTRO24 award on behalf of the STORM team honoring the legacy of Prof. Donal Hollywood. Please find the main findings below. Supported by @komop_tgkanker and @Movember

[Simon Van Wambeke @SimonWambeke]

@miszczyk_marcin Do you have any idea about reason for the conflicting results for surrogacy of PFS in mHSPC (ref 9 and 10 in the paper)?

[Simon Van Wambeke @SimonWambeke]

@petegodolphin Could you compare this analysis with https://t.co/DqTIKxCmgU where PFS does not seem to meet the criteria for surrogacy for OS in mHSPC?

[Piet Ost @piet_ost]

Open for inclusion: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial.

[Simon Van Wambeke @SimonWambeke]

@LBonneux @destandaard Eén boek te lezen dat alle data hierover begrijpelijk en zo objectief mogelijk samenvat (de RCTs passen inderdaad op één blad): https://t.co/FV75tFH6gd

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Hot off the press in @JCO_ASCO from the @csoncol team. We argue that PFS should not be used as the primary endpoint for registration trials of anti cancer drugs. https://t.co/3FJJFwiZjd @EAEisenhauer @ian_tannock #ChrisBooth

[Simon Van Wambeke @SimonWambeke]

Yes, nice piece by @joniau @EveraertsW and Thomas Van De Broeck.
Already at the ASCO 2015 presentation @ian_tannock was skeptical of the positive RTOG 0521 results.

[Dr Amol Akhade @SuyogCancer]

I am a big fan of Editorials by @EUplatinum . Short , Crisp and catchy titals . This is the latest.
The King is dead , Long live the King . 🤴
Adjuvant docetaxel in non metastatic prostate cancer.
Excellent. Congratulations to authors 👍.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

So our inaugural CSO paper- our manifesto- is just out with invitation to all stakeholders to join our movement. @csoncol is all about outcomes that matter to our patients, and how to ensure that our goals are aligned towards improving these outcomes. https://t.co/Tf2iuli3zp 1/

[Simon Van Wambeke @SimonWambeke]

@venkymd on a quest to remove dexamethasone from our armamentarium. Again a practice changing trial!

[Venky @venkymd]

#IndiaAtAsco #ASCO23
Me presenting the dexamethasone for fatigue study

[Simon Van Wambeke @SimonWambeke]

Highly relevant practice changing trial! #ASCO23

[Venky @venkymd]

#IndiaAtAsco #ASCO23
Me presenting our study on dexamethasone free antiemetic regimen

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Wow. This is exactly why there should be mandatory crossover when the drug is already SOC in later lines. We are over treating by giving cdk4/6 to everyone 1L. This trial should make news! Bringing common sense back to cancer care! @csoncol #ASCO23

[Vanita Noronha, MBBS MD DM @VanitaNoronha]

A cheap and simple intervention that prolongs DFS and OS. Amazing work from Dr Badwe, @nitaSnair
@TataMemorial @ACTREC_TMC
@OncoAlert #breastcancer
#oncology #bccww #BCSM
https://t.co/w8WorzV3vD

[Simon Van Wambeke @SimonWambeke]

New data from ICECaP “Our aggregate screening method for surrogate end points in advanced prostate cancer showed that commonly used clinical end points are not clear valid surrogate end points for OS.” https://t.co/DqTIKxCmgU

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Wondering what to read over the weekend? We have a hot-off-the-press paper on whether adjuvant pembro is really needed for renal cell cancer. This paper will also discuss not what to think but how to think about adjuvant therapies in general. https://t.co/vhePYHp1Hm